Greece: Medical Cannabis Market Overview 2025

After years of regulatory inertia, Greece’s medical cannabis market officially became operational in February 2024, marking a long-awaited turning point for both patients and investors. The first medical cannabis products became available on 19 February 2024, more than seven years after the original legalisation in 2017.

The estimated medical cannabis market size for 2025 is over €13 million, with projections suggesting growth to €XXX million by 2029 (Prohibition Partners Market Sizing Forecasts, 2025–2029).

Although Greece was among the first European countries to legalise medical cannabis, political changes and the slow development of regulatory frameworks delayed patient access for nearly a decade. This prolonged period involved complex rulemaking around cultivation, manufacturing, product approval, and clinical prescription.

The market is currently dominated by Tikun Olam, the first company to bring medical cannabis products to patients in Greece. Tikun Olam’s facility in Examilia became operational in 2024 and is presently the sole authorised supplier, with three flower strains on the market and expansion plans into extracts.

Medical cannabis imports remain prohibited, making Greece a domestically contained market for now. However, exports began in Q4 2024, with Tikun Olam shipping its first medical cannabis products to Switzerland, followed by 49 kilograms exported to Germany in Q1 2025.

Meanwhile, domestic production capacity is set to expand rapidly. Curity Pharma received its operational cultivation licence in March 2025, signalling the emergence of additional players in the market.

Greece legalised the medical use and cultivation of cannabis in 2017, reclassifying it from a Schedule A narcotic (no medical value) to Schedule D (medical value recognised). The move followed intense public advocacy from the MAMAKA patient group, which pushed for legal reform under the then-prime minister.

Subsequent legislation defined a detailed regulatory structure through several laws and decrees enacted between 2018 and 2023, including:

Under these provisions, companies are required to obtain:

Products are classified as finished pharmaceutical products, and authorisation requires full compliance with pharmaceutical standards, including:

Compared to most European markets, Greece’s marketing authorisation pathway is among the most rigorous, effectively mirroring the process for conventional pharmaceuticals.

Who Can Prescribe? Only specialist physicians are permitted to initiate medical cannabis prescriptions in Greece. Eligible specialities include:

Follow-up and Renewals: Repeat prescriptions may be conducted by a pathologist or general practitioner, provided the patient undergoes specialist review every six months.

Approved Indications:

Clinical Conditions: Prescriptions may only be issued when conventional therapies have failed, are not tolerated, or are deemed clinically infeasible for the patient.

Reimbursement: There is currently no reimbursement available for medical cannabis treatment in Greece. All costs are borne out-of-pocket by patients.

As of early 2025, three medical cannabis flower products are authorised and commercially available in Greece, all produced by Tikun Olam Hellas.

(Prices as of March 2025; Source: Tikun Olam Hellas)

Tikun Olam plans to expand its product portfolio in 2025 with the launch of extract-based products, pending marketing authorisation. The EOF also expects additional products to enter the market once other operators complete the authorisation process.

Tikun Olam Hellas currently leads Greece’s production landscape.

Curity Pharma, based in Larissa Industrial Park, received an operational licence in March 2025.

Domestic capacity is expected to increase sharply through 2026, as more companies progress through the licensing and authorisation pipeline.

Greece’s entry into active medical cannabis production and patient access in 2024 represents a watershed moment for the Southern European cannabis industry. The combination of strict pharmaceutical standards, domestic-only supply, and emerging export activity positions Greece as both a regulated patient market and an export-oriented producer.

The short-term outlook includes:

Greece is set to become a regional leader in high-standard medical cannabis production, aligning with EU pharmaceutical norms while supporting a growing domestic market.

Get granular market sizing forecasts, patient population data, and competitive intelligence across 31 European markets. Trusted by investors, operators, and regulators across the continent.